Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 157 Lung Neoplasms 73 Carcinoma, Hepatocellular 63 Small Cell Lung Carcinoma 52 Breast Neoplasms 47 Squamous Cell Carcinoma of Head and Neck 36 Urinary Bladder Neoplasms 30 Colorectal Neoplasms 30 Neoplasms 29 Biliary Tract Neoplasms 29 Neoplasm Metastasis 28 Cholangiocarcinoma 26 Triple Negative Breast Neoplasms 25 Pancreatic Neoplasms 25 Ovarian Neoplasms 24 Head and Neck Neoplasms 19 Liver Neoplasms 18 Carcinoma, Renal Cell 17 Recurrence 16 Melanoma 15 Stomach Neoplasms 13 Prostatic Neoplasms 13 Carcinoma 13 Endometrial Neoplasms 12 Uterine Cervical Neoplasms 11 Esophageal Neoplasms 11 Carcinoma, Transitional Cell 11 Lymphoma, Large B-Cell, Diffuse 10 Gallbladder Neoplasms 9 Adenocarcinoma Of Esophagus 9

Interventions

tislelizumab 2 Cystectomy 2 vistusertib 1 toripalimab 1 olaparib 1 liposomal doxorubicin 1 durvalumab 1 disitamab vedotin 1 danvatirsen 1 adavosertib 1 Surgical Procedures, Operative 1 Rutin 1 Radiation 1 RC48 antibody 1 Neoadjuvant Therapy 1 Gemcitabine 1 Cisplatin 1 Chemoradiotherapy 1 AZD4547 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle Invasive Bladder Cancer × durvalumab × Clear all

NCT02546661 2025-12-29

BISCAY

AstraZeneca

Phase 1 Active not recruiting

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡